Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday. Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations. The company’s platform helps […]

Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics. Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform.  

Nucleai, a leader in AI-powered spatial biology, and Jefferson Health, a leading cancer center, announce that they have entered into a strategic collaboration to discover spatial immunotherapy biomarkers, leveraging Nucleai’s ATOM platform and Jefferson’s repository of pathology and clinical data.

Nucleai and Merck KGaA Darmstadt Germany announced a long-term collaboration to leverage Nucleai’s image analysis and biomarker discovery

Sheba and Nucleai are working to advance the study of technological and AI-based solutions to aid in the discovery of histological biomarkers.

Nucleai’s pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system’s spatial characteristics, creating unique and specific histological